INTRODUCTION
The RhD antigen is a clinically important blood group, and the major target for maternal alloantibodies that mediate destruction of fetal red blood cells (RBC) in hemolytic disease of the newborn (HDN).
1,2 RhD-negative women pregnant with an RhD-positive child are at risk of alloimmunization due to fetomaternal hemorrhage, and exposure to RhD-positive RBC at birth.
Prophylaxis using passive anti-D immunoglobulin to block maternal immunization has reduced the incidence of HDN, but the treatment provides only temporary protection and fails in 0.5-2%
of susceptible women. 3, 4 Once RhD alloimmunization has occurred, it cannot currently be reversed. Subsequent pregnancies are at risk of HDN and require intensive monitoring, which may include invasive fetal blood sampling, 5 and treatment of serious cases relies on intrauterine transfusion, which carries up to 26% risk of adverse outcomes and 3% risk of fetal loss. 6, 7 The challenges of managing mismatched pregnancies in women who have developed anti-D antibodies have prompted a search for novel therapies that are able specifically to suppress established alloimmune responses to the RhD antigen.
The manipulation of CD4 + T-helper (Th) and T-regulatory (Treg) cell subpopulations offers a potentially effective strategy for treating the underlying responses in a wide variety of immunemediated disease, [8] [9] [10] including those in which pathology is caused by antibodies. [11] [12] [13] The vast majority of IgG antibody responses are dependent on T-cell help, and the production of antibodies specific for RBC, including anti-D, is no exception. 1, 2, 14, 15 An attractive therapeutic approach is to deliver synthetic peptides containing the dominant epitopes recognized by Thcells in such a way as to induce tolerance, rather than effector immune responses. 2, 16, 17 For example, mucosal administration of the relevant peptides can protect mice from experimental autoimmune encephalomyelitis (EAE) 16 and other inflammatory diseases, and is also beneficial in models associated with pathogenic antibodies such as autoimmune hemolytic anemia (AIHA), 11, 18 myasthenia gravis, 19 and allergy. 20 However, it has been common practice to test peptide therapy given before or soon after onset of disease, and it remains to 5 be established how effectively and rapidly antibody levels can be suppressed once responses have been established.
The most robust peptide immunotherapies induce forms of active tolerance mediated by Treg cells, 16, 21 which have the potential to control established pathogenic responses, 22 in addition to preventing them. Treg cells are characterized by expression of the transcription factor Foxp3, 23, 24 and suppress via a number of poorly defined mechanisms, including those dependent on direct cell to cell contact. 25 Although presentation of peptides via the mucosae was originally thought to be advantageous in imparting tolerance and inducing Treg cells, it is now suggested that delivery of soluble peptides systemically, such as by the subcutaneous route, can have similar therapeutic effects. 26 Recently, it has also been reported that mice are better protected in a model of allergy if multiple immunodominant peptides are administered together, 20 and, given the variation in peptide binding preferences of different MHC molecules, such combination therapy would also improve coverage of an HLA-disparate population when translated to patients. 1, 2, 27, 28 We have previously mapped peptides containing dominant helper epitopes from the RhD protein, which carries the RhD blood group. 
METHODS

Donors
RhD-negative patients with anti-D antibodies, following incompatible pregnancy, were recruited by the Scottish National Blood Transfusion Service, and samples for preparation of serum or peripheral blood mononuclear cells (PMBC) taken by venepuncture respectively into plain or lithium heparin Vacutainers (Becton Dickinson, Oxford, UK) (patient information is summarized in Table 1 ). The Grampian Health Board and the University of Aberdeen Joint
Ethical Committee approved the study and all donors gave informed consent.
Mice
Mice transgenic for HLA-DRA1*1010 and HLA-DRB1*1501, which express HLA-DR15 but not with data normalized to a standard negative control value.
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Cell culture
As previously described, 1.25x10 6 human PBMC/ml, isolated by density gradient centrifugation (Lymphoprep 1077; Nycomed Denmark), 1, 28 or 2x10 6 murine splenic mononuclear cells (SMC)/ml, 2 were cultured in alpha modification of Eagles medium (Gibco/Invitrogen, Paisley, UK) supplemented with 1% 2 mM L-glutamine (Invitrogen), 2% 20 mM HEPES buffer (Sigma, Poole, UK) and 2% penicillin streptomycin (Invitrogen), at 37 o C in a humidified atmosphere of 5% CO2/95% air. PBMC or SMC cultures were also supplemented respectively with 5% autologous serum, or 1% syngeneic serum plus 5μM 2-mercaptoethanol (Sigma). Cultures were stimulated with antigen for five days and then analyzed by proliferation assay, flow cytometry or cELISA as previously described (see supplemental information).
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Statistical analyses
Statistical differences were analyzed by parametric two-tailed t-test when similar variances were observed, or the non-parametric Mann-Whitney rank sum test, using SigmaPlot (SyStat Software).
RESULTS
Solubility of immunodominant RhD peptides
The solubility of peptides in aqueous media is important for their ability to induce immunological tolerance, and for efficiency of manufacture. 10 The four immunodominant RhD Extension to include hydrophilic residues at the termini of peptides, or selected amino acid substitutions, can improve solubility, without necessarily losing Th-cell recognition of the core epitope. 10 Therefore, a panel of modified peptides, based on the four immunodominant RhD sequences, with additional hydrophilic residues was manufactured and characterized ( Table 2 ). Of the original immunodominant peptides, only RhD 97-111 was 100% soluble when added at 5mg/ml in water, but modified versions of each of the other three sequences that were soluble at this concentration could also be identified.
Human Th-cell recognition of RhD peptides
A key question was whether the modified RhD peptides retained Th-cell recognition. Each peptide was predicted to bind the exemplar human MHC class II molecule HLA-DR (Table 2 ), but such data alone are unreliable indicators of Th-cell responses. 34 The panel of modified
and original peptides was therefore tested for the ability to stimulate proliferation by PBMC from 13 RhD-negative donors (Table 1 ) who had developed anti-D antibodies following incompatible pregnancy ( Figure 1 ). As expected, there was a high rate of responsiveness to each of the original peptides. 1 Although most analogues were less stimulatory than the parental version, at least one modified peptide derived from each of the four original sequences induced a significant proliferative response in over 60% of donors tested ( Figure   1 ).
Selection of RhD peptides for therapeutic product (RhDP mix )
It was intended to combine peptides derived from each of the four immunodominant RhD sequences into a single therapeutic product for women with anti-D antibodies, since this would maximize both efficacy and coverage of the target population. 1, 2, 27 The criteria used to select which version of each peptide should be chosen were a low GRAVY score, high measured solubility, retention of T-cell recognition as well as minimal changes from wild-type sequence.
On this basis, RhD6 52-66 M1, RhD13 97-111 , RhD17 117-131 M1 and RhD28 177-191 M4 were chosen to comprise the RhD peptide mixture (RhDP mix ).
Treatment with RhDP mix suppresses established immune responses to the RhD protein in DR transgenic mice
The next aim was to determine whether administration of RhDP mix would suppress established immune response to the RhD protein in a pre-clinical model. Conventional mice are refractory to RhD immunization, and so we exploited the HLA-DR15 transgenic strain that mounts both Th and antibody responses to the RhD protein.
serial sampling of mice revealed that, without further intervention, the levels remained constant for at least six weeks after the final booster ( Figure 2 ). The effects of nasal and subcutaneous RhDP mix on the established antibody response were compared, since, although mucosal administration was originally thought necessary to confer tolerogenic properties on peptides, 11, 16, 18, 19 the novelty of the route may impede regulatory approval of any subsequent human trial, and there is now evidence in other systems that soluble peptides may also be suppressive via more conventional delivery. 35 Although tolerance in other models has been induced by repeated low doses of peptide, a single, larger administration can also be effective, and the RhDP mix was given using the latter approach, since it represents the more practical regimen for human use. The dosage chosen, 100μg of each peptide, reflects experience elsewhere. 16, 36, 37 The kinetics of changes in antibody levels between serial blood samples from individual mice are illustrated in Figure 2A , and the results are summarized in Representative analyses are illustrated in Figure 4A , and the data summarized in Figure 4B . The table shows the age, the approximate date of previous exposure to RhD through pregnancy and the anti-D levels at recruitment for each blood donor. 
TABLES
Supplemental Methods
Isolation of effector and regulatory T cells
Effector and regulatory T cells were fractionated from SMC on the basis of CD25 expression using commercially available magnetic sorting kits (Miltenyi Biotech) and cultured at different ratios, together with 1x10 6 /ml irradiated T cell-depleted SMC as a source of antigen presenting cells.
Measurement of T cell proliferation and cytokine production
Cell proliferation was estimated from the incorporation of 
Flow cytometry
After fixation and permeabilization (buffer from eBioscience, UK), non-specific binding blocked with 2% normal rat serum (eBioscience) and SMC were stained with appropriate combinations of the following antibodies: CD4-FITC (eBioscience), CD4-PerCP (BD, UK), CD25-Pacific Blue (Biolegend, UK), Foxp3-PE (eBioscience) and Helios-APC (Biolegend).
Samples were acquired on the BD LSR II and analyses performed with FlowJo (Tree Star, UK) or FCS express (De Novo, UK) software.
Murine antibody quantification
Blood was collected from the tail vein and serum IgG antibody capable of binding human RhD-positive RBC (R 2 R 2 ) measured by a sensitive indirect enzyme-linked antiglobulin test, 1 with data normalized to a standard negative control value.
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The assay is precise (coefficient of variance <5%), capable of detecting low levels of sensitization (<500 molecules IgG per RBC), and results presented as absorbance (optical density, OD)
demonstrate an approximately linear relationship with levels of bound IgG. 4 The percentage reduction in anti-RBC antibody levels is calculated from the difference between absorbance, corrected for background OD, measured in the sera of individual mice at weeks 6 and 10 after the beginning of the immunization schedule. In some experiments, the levels of the isotypes IgG 1 and IgG 2a binding to RBC were determined using subclass-specific reagents (Jackson Immunologicals, UK). 4 
